Effects of Tuberculosis and Its Treatment on Lung and Gut Microbiota: A Comprehensive Global Review and Meta-Analysis Using Amplicon-Based Metagenomics

Category	Detail
Condition	Tuberculosis (TB)
Key Mechanisms	Impact of TB on lung and gut microbiota composition and diversity, influenced by immune responses and anti-TB treatment.
Target Population	Individuals diagnosed with tuberculosis.
Care Setting	Global health settings, including regions with varying TB prevalence.

TB is the leading infectious killer, causing 1.25 million deaths in 2023.
Microbiome studies reveal significant differences in lung and gut microbiota between TB patients and healthy individuals.
Anti-TB treatment alters microbiota composition, potentially impacting treatment outcomes.
Dysbiosis in TB patients is linked to immune-driven changes in the lungs and treatment effects in the gut.
Research highlights the need for targeted microbiota-based interventions such as prebiotics and probiotics.

Utilize microbiota signatures as potential diagnostic and prognostic biomarkers for TB.

Consider the impact of anti-TB treatment on microbiota when developing treatment plans.

Monitor changes in microbiota composition during and after TB treatment to assess treatment response.

Patients diagnosed with tuberculosis undergoing treatment.

Anti-TB medications can significantly alter gut microbiota, necessitating consideration of microbiota health in treatment strategies.

Integrate microbiome analysis into TB research to enhance understanding of disease mechanisms.
Employ mixed-methods approaches for comprehensive assessment of microbiota in TB patients.
Promote research on microbiota-based interventions to improve TB treatment outcomes.

Clinical Scorecard: Effects of Tuberculosis and Its Treatment on Lung and Gut Microbiota: A Comprehensive Global Review and Meta-Analysis Using Amplicon-Based Metagenomics